Odyssey Posts $53.1M Q3 Loss, $387M Cash Funds Runway Into H2 2028
ODTX sits 43% above its 52-week low of $15.1.
Summary
Odyssey reported a Q3 net loss of $53.1 million versus $35.5 million a year earlier, with R&D spending up to $42.1 million from $26.3 million as the OD-001 ulcerative colitis program advances. Cash, equivalents and marketable securities stood at $387 million as of September 30, which the company says funds operations into the second half of 2028. Pipeline updates: OD-002 (SLC15A4 inhibitor) finished IND-enabling studies with a Phase 1/2a trial planned for the first half of 2027, and a development candidate was nominated for OD-004, a TSLP/IL-33 bispecific. The company also named Anthony Opipari chief medical officer and Laura Hare chief people officer. The key value driver remains OD-001, with topline induction data from the Phase 2b monotherapy trial and the Phase 2a combination trial with vedolizumab expected in the second half of 2027.
At the time of this announcement, ODTX was trading at $21.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $15.10 to $29.05. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.